The ELAD study is designed to evaluate the effect of a drug that is already used for the treatment of diabetes, in Alzheimer’s disease (AD). Diabetes has been identified as a risk factor for AD and it has been shown that regulation of insulin is abnormal in AD brains.
Patients who wish to participate must fit the following criteria:
· Capacity to give consent
· A study partner (relative or friend)
· Diagnosis of probable Alzheimer’s Disease
· Age 50+
· MMSE score of >20
· On stable medication for 2 months before the screening visit; on or off cholinesterase inhibitors.
Patients are required to attend Hammersmith Hospital in London for a brain scan at the beginning and end of the trial to see what effects the study medicine has had, how it affects the memory and the structure of the brain. Patients are fully reimbursed for travel costs.
There will also be follow-up visits taking place at Penn Hospital for physical health monitoring and memory assessments.
The drug is injected (a prefilled pen) every day under the skin of the abdomen, thigh or upper arm.